Skip to main content

Kite to launch mid-stage leukemia trial in fourth quarter 2017

CHICAGO, June 5 (Reuters) - Kite Pharma Inc said on Monday it planned to launch in the fourth quarter of this year a Phase 2 trial of its experimental T-cell therapy in leukemia patients, possibly at a lower dose than is currently being tested.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.